Palumbo Wealth Management LLC Makes New $129,000 Investment in NeuroPace, Inc. (NASDAQ:NPCE)

Palumbo Wealth Management LLC purchased a new position in shares of NeuroPace, Inc. (NASDAQ:NPCE) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 11,517 shares of the company’s stock, valued at approximately $129,000.

Several other hedge funds have also recently added to or reduced their stakes in NPCE. Financial Advocates Investment Management lifted its stake in NeuroPace by 20.0% during the third quarter. Financial Advocates Investment Management now owns 18,000 shares of the company’s stock worth $125,000 after purchasing an additional 3,000 shares during the last quarter. State Street Corp lifted its stake in NeuroPace by 9.1% during the third quarter. State Street Corp now owns 155,490 shares of the company’s stock worth $1,084,000 after purchasing an additional 12,912 shares during the last quarter. Barclays PLC lifted its stake in shares of NeuroPace by 346.0% in the 3rd quarter. Barclays PLC now owns 20,633 shares of the company’s stock valued at $144,000 after acquiring an additional 16,007 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of NeuroPace by 8.7% in the 3rd quarter. Geode Capital Management LLC now owns 317,192 shares of the company’s stock valued at $2,211,000 after acquiring an additional 25,330 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in shares of NeuroPace by 106.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 11,997 shares of the company’s stock valued at $84,000 after acquiring an additional 6,181 shares during the last quarter. Institutional investors own 78.83% of the company’s stock.

Insider Activity at NeuroPace

In related news, insider Martha Morrell sold 3,200 shares of the business’s stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $15.01, for a total transaction of $48,032.00. Following the transaction, the insider now owns 87,062 shares in the company, valued at $1,306,800.62. The trade was a 3.55 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 22.20% of the stock is owned by company insiders.

NeuroPace Stock Up 1.8 %

Shares of NASDAQ:NPCE opened at $12.31 on Monday. NeuroPace, Inc. has a 1 year low of $5.45 and a 1 year high of $18.15. The company has a market cap of $367.45 million, a PE ratio of -12.31 and a beta of 2.05. The company has a debt-to-equity ratio of 6.03, a current ratio of 5.59 and a quick ratio of 4.77. The stock’s 50-day moving average is $12.25 and its 200 day moving average is $9.23.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on NPCE shares. Wells Fargo & Company boosted their target price on NeuroPace from $13.00 to $17.00 and gave the company an “overweight” rating in a research note on Thursday, January 30th. JPMorgan Chase & Co. boosted their target price on NeuroPace from $9.00 to $14.00 and gave the company an “overweight” rating in a research note on Tuesday, December 17th. Finally, UBS Group started coverage on NeuroPace in a research note on Tuesday, January 21st. They issued a “buy” rating and a $17.00 target price for the company. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, NeuroPace currently has a consensus rating of “Moderate Buy” and a consensus target price of $14.80.

NeuroPace Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.